Full text is available at the source.
Abstract
Pharmacotherapy now prioritizes cardiorenal protection using sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists.
- Modern diabetes treatment is shifting from a focus on glucose levels to a risk-adapted approach that considers individual patient needs.
- Differentiated phenotyping allows for the early identification of organ-specific risks in individuals with diabetes.
- SGLT2 inhibitors and GLP-1 receptor agonists may reduce cardiovascular events beyond just lowering blood sugar levels.
- Continuous glucose monitoring (CGM) offers dynamic metrics, such as time in range, that enhance traditional diabetes management.
- Metabolic remission is becoming a realistic therapeutic goal, especially when interventions occur early during prediabetes.
Simplified